{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:54Z","timestamp":1777564494921,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["CHEST"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.chest.2022.02.038","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T23:58:12Z","timestamp":1646351892000},"page":"297-308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma"],"prefix":"10.1016","volume":"162","author":[{"given":"Mark H.","family":"Moss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Castro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola A.","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ludwig-Sengpiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh","family":"Saralaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafal","family":"Dobek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u00f1igo","family":"Ojanguren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Vyshnyvetskyy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Bruey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1146-9915","authenticated-orcid":false,"given":"Robin","family":"Osterhout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy-ann","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kartik","family":"Raghupathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hector","family":"Ortega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chest.2022.02.038_bib2","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.jaci.2013.01.035","article-title":"Prostaglandin D2 pathway upregulation: relation to asthma severity, control, and TH2 inflammation","volume":"131","author":"Fajt","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.chest.2022.02.038_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fmed.2017.00104","article-title":"Prostaglandins and their receptors in eosinophil function and as therapeutic\u00a0targets","volume":"4","author":"Peinhaupt","year":"2017","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.chest.2022.02.038_bib4","first-page":"165","article-title":"CRTH2 antagonists in asthma: current perspectives","volume":"9","author":"Singh","year":"2017","journal-title":"Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.chest.2022.02.038_bib5","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1056\/NEJMe0900334","article-title":"Eosinophils in asthma-closing the loop or opening the door?","volume":"360","author":"Wenzel","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.chest.2022.02.038_bib6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13601-019-0282-7","article-title":"Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations","volume":"9","author":"Price","year":"2019","journal-title":"Clin Transl Allergy"},{"issue":"7","key":"10.1016\/j.chest.2022.02.038_bib7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2022.02.038_bib8","first-page":"A3019","article-title":"Pharmacokinetics, pharmacodynamics, and safety of GB001 in healthy non-Asian, non-Japanese Asian and Japanese subjects [abstract]","volume":"201","author":"Shen","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"40","key":"10.1016\/j.chest.2022.02.038_bib9","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.jaip.2019.11.016","article-title":"A\u00a0phase 2a study of DP2 antagonist GB001 for asthma","volume":"8","author":"Asano","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"suppl","key":"10.1016\/j.chest.2022.02.038_bib10","doi-asserted-by":"crossref","first-page":"AB20","DOI":"10.1016\/j.jaci.2019.12.789","article-title":"Effect of the DP2 antagonist, GB001, on asthma worsening in patients with mild-moderate asthma [abstract]","volume":"145","author":"Asano","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.chest.2022.02.038_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14728214.2016.1244262","article-title":"Are emerging PGD2 antagonists a promising therapy class for treating asthma?","volume":"21","author":"Farne","year":"2016","journal-title":"Expert Opinion Emerg Drugs"},{"issue":"12","key":"10.1016\/j.chest.2022.02.038_bib12","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-017-0777-2","article-title":"Targeting the PGD2\/CRTH2\/DP1 signaling pathway in asthma and allergic disease: current status and future perspectives","volume":"77","author":"Kupczyk","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.chest.2022.02.038_bib13","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12931-018-0912-y","article-title":"Efficacy and safety of antagonists for chemoattractant receptor-homologous molecule expressed on Th2 cells in adult patients with asthma: a meta-analysis and systematic review","volume":"19","author":"Yang","year":"2018","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.chest.2022.02.038_bib14","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1164\/rccm.201903-0599LE","article-title":"Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide, and their combination in severe asthma: a post hoc analysis","volume":"200","author":"Shrimanker","year":"2019","journal-title":"Am J Resp Crit Care Med"},{"issue":"20","key":"10.1016\/j.chest.2022.02.038_bib15","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/jama.2014.5052","article-title":"Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial","volume":"311","author":"Castro","year":"2014","journal-title":"JAMA"},{"issue":"26","key":"10.1016\/j.chest.2022.02.038_bib16","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.chest.2022.02.038_bib17","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-2600(17)30218-7","article-title":"A\u00a0novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomized controlled trials","volume":"5","author":"Fuhlbrigge","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.chest.2022.02.038_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-2600(20)30412-4","article-title":"Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomized controlled trials","volume":"9","author":"Brightling","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2022.02.038_bib19","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2147\/DDDT.S147389","article-title":"Efficacy and safety of the CRTh2 antagonist AZD1981 as add-on therapy to inhaled corticosteroids and long-acting \u03b22-agonists in patients with atopic asthma","volume":"12","author":"Bateman","year":"2018","journal-title":"Drug Des Devel Ther"}],"container-title":["CHEST"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222004056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369222004056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T01:01:44Z","timestamp":1715130104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369222004056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0012369222004056"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2022.02.038","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a Phase 2b Trial With GB001, a Prostaglandin D2 Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma","name":"articletitle","label":"Article Title"},{"value":"CHEST","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2022.02.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc under license from the American College of Chest Physicians.","name":"copyright","label":"Copyright"}]}}